6 completed, 1 active not recruiting, 1 terminated. 8 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 6, Active not recruiting 1, Terminated 1 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
Follow Capricor Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intravenous Infusion of CAP-1002 in Patients With COVID-19 CAP-1002, Placebo - Covid19 | Phase 2 | Completed | Capricor Inc. | 55 | 2020-11-15 | 2025-02-20 |
| Open-label Extension of the HOPE-2 Trial Deramiocel (CAP-1002) - Duchenne Muscular Dystrophy | Phase 2 | Active not recruiting | Capricor Inc. | 13 | 2020-08-05 | 2026-09-22 |
| Halt cardiomyOPathy progrEssion in Duchenne (HOPE-OLE) Allogeneic Cardiosphere-Derived Cells (CAP-1002) - Duchenne Muscular Dystrophy | Phase 2 | Completed | Capricor Inc. | 8 | 2018-06-21 | 2024-04-24 |
| A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy CAP-1002, Placebo - Muscular Dystrophies, Muscular Dystrophy, Duchenne | Phase 2 | Completed | Capricor Inc. | 20 | 2018-04-04 | 2025-05-28 |
| HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne) Allogeneic Cardiosphere-Derived Cells (CAP-1002) - Duchenne Muscular Dystrophy, Cardiomyopathy | Phase 2 | Completed | Capricor Inc. | 25 | 2016-01-07 | 2025-01-09 |
| Safety Study of Cenderitide in Chronic Stable Heart Failure With Moderate Renal Impairment Cenderitide, Placebo - Heart Failure, Renal Insufficiency | Phase 1 / Phase 2 | Completed | Capricor Inc. | 8 | 2015-12-01 | 2020-02-11 |
| Safety Study of Cenderitide in Stable Chronic Heart Failure Cenderitide - Heart Failure | Phase 2 | Completed | Capricor Inc. | 14 | 2015-01-01 | 2020-02-11 |
| Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration CAP-1002 Allogeneic Cardiosphere-Derived Cells, Placebo - Myocardial Infarction | Phase 1 / Phase 2 | Terminated | Capricor Inc. | 135 | 2012-11-13 | 2024-04-09 |
Muscular Dystrophy, Duchenne (4) · Heart Failure (3) · Cardiomyopathies (2) · Muscular Dystrophies (2) · COVID-19 (1) · Genetic Diseases, Inborn (1) · Genetic Diseases, X-Linked (1) · Muscular Diseases (1) · Muscular Disorders, Atrophic (1) · Myocardial Infarction (1) · Nervous System Diseases (1) · Neuromuscular Diseases (1) · Renal Insufficiency (1) · Ventricular Dysfunction, Left (1)
cenderitide (2) · chenodeoxycholate sulfate conjugate (2)
United States (8)
Mark Awadalla (3) · Craig McDonald, MD (2) · Deborah Ascheim, MD (1) · Frank Litvack, MD (1) · Joel Neutel, MD (1) · Tim Albertson, MD (1)
PMID 32749459, PMID 34233913, PMID 35279258
RC3HL103356-01 (1)